HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine ...

Editorial note: Forbes Advisor Australia may earn revenue from this story in the manner disclosed here. Read our advice disclaimer here. Australia’s recession risk increased sharply throughout ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

There are 37 top universities in Australia, according to Times Higher Education’s World University Rankings 2025, and six of them feature in the prestigious top 100, meaning there is no shortage of ...

Now more than 40 years since the discovery of the HIV pandemic. 8 The results of this study provide reason for optimism that offering long-acting antiretroviral options for PrEP, as part of a flexible ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the ...